Samsung Bioepis Fights AstraZeneca Unit Over Soliris Patent
Samsung Bioepis has challenged the validity of Alexion's Soliris drug in a London court in a bid to clear its path to sell a biosimilar version of the rare blood disease...To view the full article, register now.
Already a subscriber? Click here to view full article